If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
214
results.
Updated on
16/02/2026 [06:51:00]
Results 175 to 200 of 214
Absstract of: WO2026025355A1
A taxane supramolecular nanocomposite. The supramolecular nanocomposite comprises a taxane active substance, including but not limited to paclitaxel, docetaxel, and cabazitaxel, as well as a self-assembling carrier, a high molecular polymer, and a dissolution promoter. The dissolution promoter may comprise one or more of alcohols, polybasic organic acids, and amino acids. Also disclosed are a preparation method and use of the supramolecular nanocomposite. The supramolecular nanocomposite is suitable for oral administration and topical application, providing effects such as increased local drug exposure concentration and efficacy, reduced systemic side effects, etc.
Absstract of: WO2026025348A1
An ultra-stable nanocomposite, comprising a core component, an auxiliary unit, a self-assembling carrier, and a high polymer. Also disclosed are a preparation method for the nanocomposite and use of the nanocomposite. The ratio of the core component to the auxiliary unit in the ultra-stable nanocomposite can be adjusted to prepare nanocomposites with varying proportions of the core component and the auxiliary unit. In one aspect, the performance attributes of the core component and the auxiliary unit are improved. Moreover, the stability of the assembled nanocomposite is also significantly improved, the particle size distribution of the nanocomposite is regulated, and the preparation process for the nanocomposite is simplified. The ability of the nanocomposite to resist interference from external substances is improved, and the structural integrity of the nanocomposite during gastrointestinal transport is maintained, thereby improving the delivery efficiency of functional ingredients.
Absstract of: AU2024329805A1
The disclosure provides for compositions that comprise nanocomplexes formed by complexing one or more therapeutic agents with nucleic acid fragments of varying lengths and sizes that are coated or complexed with protamine sulfate, and uses thereof, including for the treatment of cancer in a subject in need thereof.
Absstract of: EP4686417A1
The subject of the invention are nano/microcapsules with an average diameter of 0.1 µm to 5 µm having a coating with a thickness of 5 nm to 100 nm encapsulating a core, characterised in that the coating (4) of the nano/microcapsules (1) contains pectin supplied for the preparation of the nano/microcapsules (1) in the fruit pulp, and the core (3) is a water-oil nanoemulsion containing bioactive components (6, 7). The subject of the application is also a health-promoting product containing these nano/microcapsules and the method of obtaining them.
Absstract of: WO2024141955A1
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.
Absstract of: MX2025014990A
The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
Absstract of: MX2025010834A
Disclosed herein, in part, are pharmaceutical compositions comprising a prodrug of an antiviral agent and methods of using the same in the treatment of viral infections.
Absstract of: CN121445678A
本发明公开了一种针对妊娠期糖尿病合并感染的复方抗菌缓释制剂及其制备方法，涉及医药技术领域，包括以下步骤：S1、采用纳米沉淀法，将PLGA‑PEG‑酯酶底物共聚物、乳酸链球菌素和甘草酸二钾共同溶解于有机溶剂中，形成有机相；在剪切速率为5000‑10000rpm下，将所述有机相注入含有占水相重量0.5%‑2%的聚乙烯吡咯烷酮的水相中，混合；该针对妊娠期糖尿病合并感染的复方抗菌缓释制剂及其制备方法，泊洛沙姆407/壳聚糖温敏凝胶基质使得制剂在室温下为易灌注的液体，便于给药，进入阴道后，在体温下迅速转变为半固体凝胶，延长制剂在阴道内的滞留时间，实现长效缓释。
Absstract of: CN121445709A
本发明涉及一种靶向C1GALT1基因的反义肽核酸纳米颗粒递送系统及其制备方法和应用，属于生物医药和纳米技术领域。所述的纳米颗粒递送系统以PLGA‑PEG共聚物作为载体材料，负载反义γ肽核酸，有效递送至细胞，以靶向抑制C1GALT1基因表达。本发明的制备工艺简便，具有良好的生物可降解性和生物安全性；能够高效递送反义γ肽核酸，敲低B细胞中C1GALT1基因，与RNA结合稳定性高、脱靶效应低，为研究相关分子疾病提供了有效工具，具备良好的临床应用前景。
Absstract of: WO2024220625A1
Provided herein is a method for delivering an RNA composition to a subject for in vivo production of a protein or a peptide in the subject, comprising administering to the subject an RNA composition comprising a polynucleotide that encodes a protein or a peptide, formulated within (a) a plurality of lipid nanoparticles (LNP) comprising synthetic structural lipids and an ionizable lipid, or (b) a lipid reconstructed natural messenger packs (LNMPs) comprising natural lipids and an ionizable lipid. Also provided herein are methods for treating diseases or disorders associated with the gastrointestinal tract, stomach, small or large intestine, mesenteric lymph node, pancreas, colon or rectum, caecum, and/or spleen, comprising orally or enterally administering the RNA composition described herein.
Absstract of: CN121445710A
本发明涉及一种基于二烃基咪唑仿生型脂质的酶响应型脑靶向缓释制剂及其制备方法和应用，属于药物递送领域。先将二烃基咪唑仿生型脂质与天然磷脂共价偶联，形成二脂偶联物。再将该二脂偶联物与二烃基咪唑仿生型脂质、天然磷脂、胆固醇和治疗性药物自组装形成载药脂质纳米颗粒递送系统；该药物递送系统可有效穿越血脑屏障，实现所装载药物的脑靶向递送；该药物递送系统在脑胶质瘤微环境下能够通过酶响应机制逐步水解二脂偶联物，实现所装载药物的缓释，为改善小核酸药物、多肽类药物、小分子药物等不同种类抗脑胶质瘤药物的脑靶向性以及疗效提供了新策略。
Absstract of: MX2025012337A
The present disclosure is directed to the use of reconstituted mRNA dry powder particles for parenteral administration. The present disclosure is also directed to a method of generating dry powder particles supplemented with appropriate excipients for optimal thermostability and in vivo expression.
Absstract of: MX2025012841A
The current invention relates to a delivery system to deliver one or more cargo to one or more cells, wherein the cargo delivery system comprises at least a calixarene, a phospholipid, an additional lipid such as sterol. The invention further relates to a method of delivering cargo to a subject using the delivery system and a pharmaceutical composition comprising the delivery system. The invention also relates to the use of a calixarene in an immunogenic composition, wherein said composition comprises an immunogenic component encapsulated in a lipid nanoparticle (LNP) comprising said calixarene and wherein said LNP has an adjuvant effect in said immunogenic composition. The invention also relates to a vaccine, wherein said vaccine comprises an immunogenic component encapsulated in a lipid nanoparticle, wherein said lipid nanoparticle comprises at least one calixarene molecule and said lipid nanoparticle acts as an adjuvant in said vaccine. The invention also relates to a method of preparing an immunogenic composition and a composition comprising a lipid nanoparticle (LNP) adjuvant comprising calixarene.
Absstract of: MX2025012462A
The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.
Absstract of: ZA202305748B
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.
Absstract of: US20260001838A1
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve targeted delivery of therapeutic cargo without the need for a targeting ligand are also provided.
Absstract of: CN121449524A
本发明涉及一种可离子化脂质化合物及其制备方法和应用，本发明提供的可离子化脂质化合物由极性氨基头和疏水尾构成。本发明通过改变可离子化脂质化物文库中包含的多种极性氨基头和疏水尾部构建多样化的具有低免疫原性的可离子化脂质化合物的制备及应用。具有生物可降解性能的新型可离子化脂质化合物与mRNA结合能力更强，且不过度引发相关的免疫炎性反应，此外由其合成的脂质纳米颗粒具有优异的理化特征，高的细胞摄取效率，溶酶体逃逸率及细胞和体内的高转染效率。
Absstract of: CN121450645A
本发明属于生物医药与分子生物学领域，具体涉及一种新型的正交复制RNA、制备方法及其应用。所述正交复制RNA的序列包含：(a) 人诺如病毒的5'非翻译区；(b)人诺如病毒的开放阅读框1，其编码复制酶；(c) 目的基因的反义编码序列；(d) 复制终止信号和3'非翻译区；所述正交复制RNA在细胞内复制后，能够产生5'端共价连接有Vpg蛋白的、可翻译所述目的基因的正义mRNA。本申请首次将huNoV复制子成功工程化为治疗性OrepRNA平台，创造了全新的RNA药物载体类别，可以实现低免疫原性、高保真性，突破帽依赖性翻译受限的疾病治疗瓶颈。该平台通过匹配不同治疗基因可解决多种病理机制迥异的疾病，延展性强，为肿瘤恶病质、GVHD肺纤维化等难治性疾病提供突破性治疗方案。
Absstract of: CN121445905A
本发明涉及一种肿瘤内质网靶向的稀土纳米诊疗一体化制剂及其制备方法和应用，所述稀土纳米诊疗一体化制剂包括稀土核壳纳米颗粒以及负载在稀土核壳纳米颗粒表面的肿瘤靶向肽和内质网信号肽；所述稀土核壳纳米颗粒包括稀土纳米颗粒NaYbF4:Er/Ce/Zn和覆盖于NaYbF4表面的CaF2。该稀土纳米诊疗一体化制剂能够依赖精准的内质网靶向Ca²⁺释放，诱导肿瘤细胞钙过载，从而触发免疫原性细胞死亡并激活抗肿瘤免疫反应；同时，借助稀土纳米颗粒稳定的NIR‑Ⅱ区荧光特性，实现对肿瘤病灶的高灵敏成像与实时监测，兼具精准诊断与高效治疗的一体化优势。
Absstract of: CN121445708A
本发明涉及一种靶向递送丁酸的OSA淀粉‑多糖互穿网络微球的制备方法，包括：S1、将多孔淀粉与辛烯基琥珀酸酐进行酯化反应，得到OSA淀粉；S2、将丁酸钠与玉米醇溶蛋白溶于醇溶液中，搅拌进行包埋，得到玉米醇溶蛋白‑丁酸钠；S3、将OSA淀粉与玉米醇溶蛋白‑丁酸钠进行反应，得到复合物；S4、将复合物分散于海藻酸钠溶液中，再滴加到氯化钙溶液中进行交联，得到OSA淀粉‑多糖凝胶微球，然后将其浸泡于第一浓度的壳聚糖溶液中进行一次包覆，再浸泡于第二浓度的壳聚糖溶液中进行二次包覆；第一浓度低于第二浓度，第一浓度和第二浓度相差不低于1wt％。本发明通过构建内核‑载体‑互穿网络外壳的结构，解决丁酸递送中包封率低、靶向性差、稳定性弱的难题。
Absstract of: CN120936714A
The present invention relates to methods of environment-specific or cellular environment-specific gene regulation, as well as related nucleic acid constructs, cells and therapeutic uses and methods. In particular, the present invention relates to the inhibition of environmentally specific expression of RNA in a cell in order to regulate the expression of one or more target genes in said cell in an environmentally specific manner.
Absstract of: MX2025008266A
A mixture for treating a tumor, which includes an agent which turns into a hydrogel by addition of calcium ions, a vehicle carrying the agent in a manner allowing injection of the mixture into a tumor; and radium radionuclides bonded to the agent in a concentration sufficient to treat the tumor by radiotherapy.
Absstract of: CN120835876A
The present invention relates to: an ionized lipid comprising a lipid having a branched structure; lipid nanoparticle formulations using the ionized lipids and uses thereof. The ionized lipid provided by the invention is a biodegradable lipid material, and a branched heteroamine structure exists in the lipid structure of the ionized lipid. Moreover, the lipid nanoparticles using the ionized lipid can efficiently deliver nucleic acid drugs and the like, and thus can be effectively used in related technical fields, such as mRNA vaccines and therapeutic agents.
Absstract of: CN120897991A
The present invention relates to chimeric antigen receptor constructs and their use for therapy and therapy. Further disclosed are methods of treating and/or preventing a disease such as, for example, cancer, an infectious disease, an inflammatory or inflammation-inducing disease, a chronic disease, or an autoimmune disease.
Nº publicación: MX2025011537A 03/02/2026
Applicant:
SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD [CN]
SHENZHEN MAGICRNA BIOTECHNOLOGY CO., LTD
Absstract of: MX2025011537A
The present invention provides an amino lipid, and lipid nanoparticles (LNPs) and a use thereof, the amino lipid having a structure represented by general formula (I), or an isomer, pharmaceutically acceptable salt, prodrug or solvate of the amino lipid. The present invention further provides LNPs containing the amino lipid. According to the present invention, the amino lipid having a structure represented by general formula (I) is used as an ionizable lipid compound, and the LNPs are obtained by means of self-assembly of the ionizable lipid compound, a steroid, a neutral lipid, and a polymer-bonded lipid. The LNPs can further improve the translation expression level of a nucleic acid load in cells, improve the effect of a nucleic acid-LNP preparation, and enable the nucleic acid-LNP preparation to provide a theoretical basis for personalized treatment.
BOPI
Electronic site
